CL2017001372A1 - Composiciones anticancerosas - Google Patents
Composiciones anticancerosasInfo
- Publication number
- CL2017001372A1 CL2017001372A1 CL2017001372A CL2017001372A CL2017001372A1 CL 2017001372 A1 CL2017001372 A1 CL 2017001372A1 CL 2017001372 A CL2017001372 A CL 2017001372A CL 2017001372 A CL2017001372 A CL 2017001372A CL 2017001372 A1 CL2017001372 A1 CL 2017001372A1
- Authority
- CL
- Chile
- Prior art keywords
- arn
- castration
- cancer
- copylimer
- acrylate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A FORMULACIONES FARMACÉUTICAS DE ARN-509 QUE PUEDEN SER ADMINISTRADAS A UN MAMÍFERO, PARTICULARMENTE A UN SER HUMANO, QUE PADECE DE UNA ENFERMEDAD O AFECCIÓN RELACIONADA CON EL RECEPTOR ANDROGÉNICO KPA) , PARTICULARMENTE CÁNCER, MÁS PARTICULARMENTE CÁNCER DE PRÓSTATA, INCLUIDOS, A TÍTULO MERAMENTE ENUNCIATIVO, CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN, CÁNCER DE PRÓSTATA CON METÁSTASIS RESISTENTE A LA CASTRACIÓN, CÁNCER DE PRÓSTATA CON METÁSTASIS RESISTENTE A LA CASTRACIÓN SIN TRATAMIENTO PREVIO CON QUIMIOTERAPIA, CÁNCER DE PRÓSTATA SENSIBLE A LAS HORMONAS CON RECIDIVA BIOQUÍMICA O CÁNCER DE PRÓSTATA NO METASTÁSICO RESISTENTE A LA CASTRACIÓN Y DE ALTO RIESGO. EN UN ASPECTO, ESTAS FORMULACIONES COMPRENDEN UNA DISPERSIÓN SÓLIDA DE ARN-509 Y UN COPOLÍMERO DE POLI(MET)ACRILATO. EN UN ASPECTO, LA DISPERSIÓN SÓLIDA DE ARN-509 Y UN COPOLÍMERO DE POLI(MET)ACRILATO SE PUEDE OBTENER, PARTICULARMENTE SE OBTIENE, MEDIANTE LA EXTRUSIÓN POR FUSIÓN DE UNA MEZCLA QUE COMPRENDE ARN-509 Y UN COPOLÍMERO DE POLI(MET)ACRILATO Y, OPCIONALMENTE, MOLIENDO POSTERIORMENTE DICHA MEZCLA EXTRUDIDA POR FUSIÓN. EN UN ASPECTO, LA DISPERSIÓN SÓLIDA DE ARN-509 Y UN COPOLÍMERO DE POLI(MET)ACRILATO SE PUEDE OBTENER, PARTICULARMENTE SE OBTIENE, MEDIANTE LA DESHIDRATACIÓN POR ASPERSIÓN DE UNA MEZCLA QUE COMPRENDE ARN-509 Y UN COPOLÍMERO DE POLI (MET)ACRILATO EN UN DISOLVENTE ADECUADO.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196591 | 2014-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001372A1 true CL2017001372A1 (es) | 2018-01-05 |
Family
ID=52006905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001372A CL2017001372A1 (es) | 2014-12-05 | 2017-05-29 | Composiciones anticancerosas |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20170360707A1 (es) |
| EP (2) | EP3226842B1 (es) |
| JP (1) | JP6767368B2 (es) |
| KR (1) | KR102348325B1 (es) |
| CN (2) | CN106999430A (es) |
| AR (1) | AR102924A1 (es) |
| AU (1) | AU2015358493B2 (es) |
| CA (1) | CA2969661C (es) |
| CL (1) | CL2017001372A1 (es) |
| CO (1) | CO2017005573A2 (es) |
| CR (1) | CR20170217A (es) |
| CY (1) | CY1123856T1 (es) |
| DK (1) | DK3226842T3 (es) |
| EA (1) | EA035988B1 (es) |
| ES (1) | ES2839128T3 (es) |
| HR (1) | HRP20201902T1 (es) |
| HU (1) | HUE051888T2 (es) |
| IL (1) | IL252324B (es) |
| LT (1) | LT3226842T (es) |
| MA (2) | MA41108B1 (es) |
| MD (1) | MD3226842T2 (es) |
| MX (1) | MX2017007201A (es) |
| NI (1) | NI201700069A (es) |
| PL (1) | PL3226842T3 (es) |
| PT (1) | PT3226842T (es) |
| RS (1) | RS61466B1 (es) |
| SG (1) | SG11201704264UA (es) |
| SI (1) | SI3226842T1 (es) |
| TW (1) | TWI683662B (es) |
| UA (1) | UA121123C2 (es) |
| WO (1) | WO2016090101A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY180834A (en) | 2012-09-26 | 2020-12-10 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| MD3226843T2 (ro) | 2014-12-05 | 2021-10-31 | Aragon Pharmaceuticals Inc | Compoziții anticancer |
| AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| ES2967689T3 (es) | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
| WO2020144650A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of prostate cancer |
| WO2020157704A1 (en) | 2019-01-30 | 2020-08-06 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| EP3917519A1 (en) | 2019-01-30 | 2021-12-08 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| CA3160121A1 (en) | 2019-11-04 | 2021-05-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL365330A1 (en) | 2001-04-02 | 2004-12-27 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
| JPWO2003077827A1 (ja) * | 2002-03-19 | 2005-07-14 | 日本新薬株式会社 | 医薬固体分散体の製造方法 |
| WO2005055987A1 (en) * | 2003-12-15 | 2005-06-23 | Council Of Scientific & Industrial Research | TASTE MASKED PHARMACEUTICAL COMPOSITIONS COMPRISING BITTER DRUG AND pH SENSITIVE POLYMER |
| EP3412290B1 (en) * | 2006-03-27 | 2021-03-03 | The Regents of The University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| SI3124481T1 (en) * | 2010-02-16 | 2018-06-29 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and their use |
| WO2012174436A1 (en) * | 2011-06-15 | 2012-12-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2013152342A1 (en) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| DK3533792T3 (da) | 2012-06-07 | 2021-06-28 | Aragon Pharmaceuticals Inc | Krystallinske former af en androgenreceptormodulator |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| SI3725778T1 (sl) * | 2012-09-11 | 2022-02-28 | Medivation Prostate Therapeutics Llc | Formulacije enzalutamida |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| MY192032A (en) * | 2013-01-22 | 2022-07-24 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| CN105636594A (zh) * | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
| EA037895B1 (ru) * | 2014-02-05 | 2021-06-02 | Лек Фармасьютикалз Д.Д. | Твердые фармацевтические композиции антагонистов рецепторов андрогенов |
-
2015
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/en active Active
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh active
- 2015-12-03 MX MX2017007201A patent/MX2017007201A/es unknown
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-03 CN CN202211487545.0A patent/CN115837010A/zh active Pending
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active IP Right Grant
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 EP EP20209559.2A patent/EP3842034A1/en active Pending
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro unknown
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/en active Application Filing
- 2015-12-03 CA CA2969661A patent/CA2969661C/en active Active
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
-
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
-
2020
- 2020-11-30 HR HRP20201902TT patent/HRP20201902T1/hr unknown
-
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001372A1 (es) | Composiciones anticancerosas | |
| CL2017001371A1 (es) | Composiciones anticancerosas | |
| CL2017001373A1 (es) | Composiciones anticancerosas | |
| CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
| CU20170045A7 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
| CL2017001916A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso (divisional solicitud 468-2016) | |
| BR112019002687A2 (pt) | receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos | |
| CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
| CL2015001356A1 (es) | Anticuerpos bioespecificos egfr/c-met | |
| CL2016001743A1 (es) | Conjugados de anticuerpo-fármaco (adc) de duocarmicina para su uso en el tratamiento de cáncer de endometrio. | |
| PE20150891A1 (es) | Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco | |
| CL2014003465A1 (es) | Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer. | |
| CL2008001674A1 (es) | Dominio variable simple (dab) de inmunoglobulina anti-fator de crecimiento endotlial vascular (vegf); acido nucleoico que lo codifica; vector y celula huesped; metodo de produccion; antagonosta de vegf que comprende el dab; composiicon que comprende al antagonista; y uso del antagonista para prepara un medicamento. | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
| CL2007002085A1 (es) | Anticuerpo o fragmento del mismo especifico para el receptor epha2; polinucleotido que lo codifica; vector y celula huesped que lo comprenden; hibridoma; conjugados del mismo con agentes citotoxicos; composicion farmaceutica que los comprende;su uso | |
| CL2008002885A1 (es) | Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende | |
| CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
| MX2019015352A (es) | Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1). | |
| CR20130632A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| CL2018003403A1 (es) | Composiciones antineoplásicas. | |
| CL2015001459A1 (es) | Nueva composición farmacéutica. | |
| CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. |